[go: up one dir, main page]

DK3339303T3 - Kondenserede aryl- og heteroaryllactamer - Google Patents

Kondenserede aryl- og heteroaryllactamer Download PDF

Info

Publication number
DK3339303T3
DK3339303T3 DK17206218.4T DK17206218T DK3339303T3 DK 3339303 T3 DK3339303 T3 DK 3339303T3 DK 17206218 T DK17206218 T DK 17206218T DK 3339303 T3 DK3339303 T3 DK 3339303T3
Authority
DK
Denmark
Prior art keywords
lactams
heteroaryl
condensed aryl
condensed
aryl
Prior art date
Application number
DK17206218.4T
Other languages
English (en)
Inventor
Martin Paul Edwards
Robert Arnold Kumpf
Pei-Pei Kung
Indrawan James Mcalpine
Sacha Ninkovic
Eugene Yuanjin Rui
Scott Channing Sutton
John Howard Tatlock
Martin James Wythes
Luke Raymond Zehnder
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK3339303T3 publication Critical patent/DK3339303T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK17206218.4T 2012-12-21 2013-12-05 Kondenserede aryl- og heteroaryllactamer DK3339303T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740596P 2012-12-21 2012-12-21
EP13817739.9A EP2935238B1 (en) 2012-12-21 2013-12-05 Aryl and heteroaryl fused lactams

Publications (1)

Publication Number Publication Date
DK3339303T3 true DK3339303T3 (da) 2020-08-10

Family

ID=49917684

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13817739.9T DK2935238T3 (da) 2012-12-21 2013-12-05 Aryl- og heteroaryl-fusionerede lactamer
DK17206218.4T DK3339303T3 (da) 2012-12-21 2013-12-05 Kondenserede aryl- og heteroaryllactamer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK13817739.9T DK2935238T3 (da) 2012-12-21 2013-12-05 Aryl- og heteroaryl-fusionerede lactamer

Country Status (46)

Country Link
US (3) US9040515B2 (da)
EP (2) EP3339303B9 (da)
JP (1) JP5909308B2 (da)
KR (1) KR101712441B1 (da)
CN (1) CN104870435B (da)
AP (1) AP2015008574A0 (da)
AR (1) AR094174A1 (da)
AU (1) AU2013365908C1 (da)
BR (1) BR112015014678B1 (da)
CA (1) CA2893339C (da)
CL (1) CL2015001733A1 (da)
CR (2) CR20200273A (da)
CU (1) CU24414B1 (da)
CY (2) CY1119883T1 (da)
DK (2) DK2935238T3 (da)
DO (1) DOP2015000157A (da)
EA (1) EA028317B1 (da)
EC (1) ECSP15031579A (da)
ES (2) ES2808987T3 (da)
GE (1) GEP201706718B (da)
GT (1) GT201500190A (da)
HR (2) HRP20180060T1 (da)
HU (2) HUE050009T2 (da)
IL (1) IL239520B (da)
LT (2) LT2935238T (da)
MA (1) MA38175B1 (da)
MD (1) MD4664C9 (da)
ME (2) ME03793B (da)
MX (2) MX2015008058A (da)
MY (2) MY176307A (da)
NO (1) NO2961649T3 (da)
NZ (1) NZ708801A (da)
PE (1) PE20151090A1 (da)
PH (1) PH12015501367B1 (da)
PL (2) PL3339303T3 (da)
PT (2) PT3339303T (da)
RS (2) RS56815B1 (da)
SG (1) SG11201504076XA (da)
SI (2) SI2935238T1 (da)
TN (1) TN2015000281A1 (da)
TR (1) TR201802791T4 (da)
TW (1) TWI546293B (da)
UA (1) UA111305C2 (da)
UY (2) UY38712A (da)
WO (1) WO2014097041A1 (da)
ZA (1) ZA201504437B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
JP6284547B2 (ja) 2012-12-21 2018-02-28 アリオス バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2015023915A1 (en) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
MY185765A (en) 2014-06-17 2021-06-06 Pfizer Substituted dihydroisoquinolinone compounds
WO2015193768A1 (en) * 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
MA40848A (fr) * 2014-10-28 2021-05-05 Glaxosmithkline Ip No 2 Ltd Inhibiteurs d'ezh2 (enhancer of zeste homolog 2)
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
EP3236962A2 (en) 2014-12-23 2017-11-01 University of Copenhagen Treatment of cancer by inhibiting ezh2 activity
US10273221B2 (en) * 2015-03-27 2019-04-30 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
TW201708210A (zh) * 2015-06-30 2017-03-01 葛蘭素史克智慧財產（第二）有限公司 Ｚｅｓｔｅ同源物２增強子之抑制劑
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
CN107428742B (zh) 2015-11-19 2020-05-08 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用
CA3023157A1 (en) * 2016-05-05 2017-11-09 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
WO2018075598A1 (en) 2016-10-19 2018-04-26 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
US20200262813A1 (en) * 2016-11-11 2020-08-20 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. 1,5,7-trisubstituted isoquinoline derivatives, preparation thereof, and use thereof in medicines
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
RU2762893C2 (ru) 2017-05-18 2021-12-23 Цзянсу Хэнжуй Медсин Ко., Лтд. Применение ингибитора ezh2 в комбинации с ингибитором btk в получении лекарственного средства для лечения опухоли
AU2018269268B2 (en) 2017-05-18 2022-01-06 Jiangsu Hengrui Medicine Co., Ltd. Crystal of benzofuran derivative free base and preparation method
CN106977483A (zh) * 2017-06-02 2017-07-25 遵义医学院 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法
CA3082287C (en) 2017-11-14 2023-02-28 Pfizer Inc. Ezh2 inhibitor combination therapies
PT4043466T (pt) 2018-01-31 2024-10-14 Mirati Therapeutics Inc Inibidores de prc2
CN112533581B (zh) * 2018-06-07 2024-08-30 密歇根大学董事会 Prc1抑制剂及用其进行治疗的方法
WO2020011607A1 (en) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
EP3870173A4 (en) * 2018-10-24 2022-06-22 Vanderbilt University WDR5 INHIBITORS AND MODULATORS
CN111320582A (zh) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 一种类酰胺类衍生物及其中间体的制备方法
KR102689665B1 (ko) * 2019-02-19 2024-07-31 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
EP3959214A1 (en) 2019-04-22 2022-03-02 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
EP3980422A1 (en) 2019-06-05 2022-04-13 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
KR102386403B1 (ko) * 2020-08-13 2022-04-15 한미약품 주식회사 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도
US11535629B2 (en) * 2020-08-13 2022-12-27 Hanmi Pharmaceutical Co., Ltd. Dioxoloisoquinolinone derivatives and use thereof
WO2022179584A1 (zh) * 2021-02-26 2022-09-01 南京药石科技股份有限公司 新型ezh2抑制剂及其用途
CN120476107A (zh) 2022-12-15 2025-08-12 先正达农作物保护股份公司 可用作杀有害生物剂的新型的二环-甲酰胺化合物
CN118978498B (zh) * 2024-10-22 2025-04-01 浙江雅辰药物科技股份有限公司 一种5-羟甲基四氢呋喃-3-醇的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846412A (en) 1971-03-18 1974-11-05 Lepetit Spa Dihydro-2-amino-isoquinolines and their derivatives
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
MX2008002207A (es) 2005-08-16 2008-03-27 Memory Pharm Corp Inhibidores de fosfodiesterasa 10.
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
WO2011140325A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
US8637509B2 (en) 2010-05-07 2014-01-28 Glaxosmithkline Llc Azaindazoles
EP2566327B1 (en) 2010-05-07 2017-03-29 Glaxosmithkline LLC Indoles
PL2614369T3 (pl) 2010-09-10 2016-08-31 Epizyme Inc Sposób określania przydatności inhibitorów ludzkiego ezh2 w leczeniu
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JP2014511389A (ja) * 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換６，５−縮合二環式ヘテロアリール化合物
TW201733984A (zh) * 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
BR112014007603A2 (pt) 2011-09-30 2017-06-13 Glaxosmithkline Llc métodos de tratamento do câncer
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
WO2014049488A1 (en) 2012-09-28 2014-04-03 Pfizer Inc. Benzamide and heterobenzamide compounds
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
DK3067358T3 (da) 2012-12-21 2019-11-04 Gilead Sciences Inc Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse
FR3000065A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
BR112015014752B1 (pt) 2012-12-21 2022-07-05 Plexxikon, Inc Compostos e seus uso para modulação de cinase
PT2934568T (pt) 2012-12-21 2018-01-04 Sanofi Sa Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina
EP3498701B1 (en) 2012-12-21 2023-02-22 Epizyme Inc Prmt5 inhibitors and uses thereof
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
CN104870466B (zh) 2012-12-21 2018-05-18 霍夫曼-拉罗奇有限公司 作为催产素激动剂的肽
FR3000059A1 (fr) 2012-12-21 2014-06-27 Saint Gobain Placo Composition pour plaques de platre et produits obtenus
JP6284547B2 (ja) 2012-12-21 2018-02-28 アリオス バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
MY185765A (en) 2014-06-17 2021-06-06 Pfizer Substituted dihydroisoquinolinone compounds

Also Published As

Publication number Publication date
SI2935238T1 (en) 2018-04-30
HRP20201194T1 (hr) 2020-11-13
KR101712441B1 (ko) 2017-03-07
EA028317B1 (ru) 2017-11-30
CY1119883T1 (el) 2018-06-27
AP2015008574A0 (en) 2015-07-31
HRP20201194T2 (hr) 2021-09-17
ES2808987T9 (es) 2021-11-29
US20140179667A1 (en) 2014-06-26
EP3339303B9 (en) 2021-07-21
SI3339303T1 (sl) 2020-09-30
JP2016507497A (ja) 2016-03-10
MD4664B1 (ro) 2019-12-31
US10246433B2 (en) 2019-04-02
PH12015501367B1 (en) 2018-08-03
MD20150052A2 (ro) 2015-12-31
CR20200273A (es) 2020-09-23
IL239520A0 (en) 2015-08-31
TW201446753A (zh) 2014-12-16
EP2935238A1 (en) 2015-10-28
TR201802791T4 (tr) 2018-03-21
RS60582B1 (sr) 2020-08-31
US20170233368A1 (en) 2017-08-17
LT2935238T (lt) 2018-02-26
IL239520B (en) 2018-05-31
ME02980B (me) 2018-10-20
EA201590879A1 (ru) 2015-12-30
MY192259A (en) 2022-08-12
UY35225A (es) 2014-07-31
BR112015014678B1 (pt) 2021-12-07
DOP2015000157A (es) 2015-11-30
PT2935238T (pt) 2018-02-09
SG11201504076XA (en) 2015-06-29
EP3339303A1 (en) 2018-06-27
LT3339303T (lt) 2020-09-10
MD4664C9 (ro) 2020-07-31
ME03793B (me) 2021-04-20
AU2013365908B2 (en) 2017-07-20
CR20150279A (es) 2015-09-03
ECSP15031579A (es) 2017-08-31
TN2015000281A1 (fr) 2016-10-03
JP5909308B2 (ja) 2016-04-26
UY38712A (es) 2020-06-30
AR094174A1 (es) 2015-07-15
PE20151090A1 (es) 2015-08-07
AU2013365908A1 (en) 2015-06-11
HUE038238T2 (hu) 2018-10-29
MA38175B1 (fr) 2018-11-30
PH12015501367A1 (en) 2015-09-02
CY1123237T1 (el) 2021-10-29
NO2961649T3 (da) 2018-02-17
CN104870435B (zh) 2016-12-07
CL2015001733A1 (es) 2015-10-23
EP2935238B1 (en) 2017-12-27
CU24414B1 (es) 2019-05-03
MX2020002924A (es) 2020-07-22
PL3339303T3 (pl) 2021-01-25
HK1208866A1 (en) 2016-03-18
MA38175A1 (fr) 2018-08-31
GEP201706718B (en) 2017-08-10
NZ708801A (en) 2018-08-31
PL2935238T3 (pl) 2018-05-30
CU20150062A7 (es) 2015-11-27
ES2808987T3 (es) 2021-03-02
TWI546293B (zh) 2016-08-21
AU2013365908C1 (en) 2018-01-25
HUE050009T2 (hu) 2020-11-30
MY176307A (en) 2020-07-28
HRP20180060T1 (hr) 2018-02-23
PT3339303T (pt) 2020-07-30
GT201500190A (es) 2016-01-21
CA2893339A1 (en) 2014-06-26
EP3339303B1 (en) 2020-06-24
RS60582B9 (sr) 2021-09-30
ES2658974T3 (es) 2018-03-13
CA2893339C (en) 2017-06-13
RS56815B1 (sr) 2018-04-30
US20150175572A1 (en) 2015-06-25
CN104870435A (zh) 2015-08-26
DK2935238T3 (da) 2018-01-22
KR20150100823A (ko) 2015-09-02
UA111305C2 (uk) 2016-04-11
US9040515B2 (en) 2015-05-26
BR112015014678A2 (pt) 2017-07-11
ZA201504437B (en) 2016-07-27
MX2015008058A (es) 2015-10-30
WO2014097041A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
DK3339303T3 (da) Kondenserede aryl- og heteroaryllactamer
EP2872093A4 (en) DIAPER PANTS
BR302013000038S1 (pt) Configuração aplicada em recipiente
EP2807309A4 (en) ABFLUSSSIEB
EP2872089A4 (en) CONTAINMENT TROUSERS
DE102013212915A8 (de) Trägheitssensor
EP2884134A4 (en) HEAT REGULATORS
BR302012005494S1 (pt) Configuracao aplicada em recipiente
EP2888965A4 (en) KIMONO
EP2842163A4 (en) NONLINEAR MEMRISTORS
BR302012005495S1 (pt) Configuracao aplicada em recipiente
BR112015008584A2 (pt) conjunto de fixador
EP2814629A4 (en) LEAK DETECTION SYSTEM
BR302013001715S1 (pt) Configuração aplicada em espigão
BR302013001719S1 (pt) Configuração aplicada em beiral
EP2831809A4 (en) SAFETY FEATURE
DE102012001057A8 (de) Bauteil
BR112015010293A2 (pt) dispositivo de bloqueio
UA24741S (uk) Вішалка
BR302012000668S1 (pt) Cabide
ES1104005Y (es) Desactivador
ES1076627Y (es) Dispositivo de bloqueo
BR302012001879S1 (pt) Configuração aplicada em liquidificador ou similar
BR302012003269S1 (pt) Configuração aplicada em assador vertical
BR302012006628S1 (pt) Configuração aplicada em puxador